{Reference Type}: Journal Article
{Title}: Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development.
{Author}: Cruciani C;Gatto M;Iaccarino L;Doria A;Zen M;
{Journal}: Expert Opin Investig Drugs
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 3
{Factor}: 6.498
{DOI}: 10.1080/13543784.2024.2376566
{Abstract}: <B>UNASSIGNED: </B>the advent of biological therapies has already revolutionized treatment strategies and disease course of several rheumatologic conditions, and monoclonal antibodies (mAbs) targeting cytokines and interleukins represent a considerable portion of this family of drugs. In Systemic Lupus Erythematosus (SLE) dysregulation of different cytokine and interleukin-related pathways have been linked to disease development and perpetration, offering palatable therapeutic targets addressable via such mAbs.<BR><B>UNASSIGNED: </B>In this review, we provide an overview of the different biological therapies under development targeting cytokines and interleukins, with a focus on mAbs, while providing the rationale behind their choice as therapeutic targets and analyzing the scientific evidence linking them to SLE pathogenesis.<BR><B>UNASSIGNED: </B>an unprecedented number of clinical trials on biological drugs targeting different immunological pathways are ongoing in SLE. Their success might allow us to tackle present challenges of SLE management, including the overuse of glucocorticoids in daily clinical practice, as well as SLE heterogenicity in treatment response among different individuals, hopefully paving the way toward precision medicine.